Here's 1 Reason Endo Pharmaceuticals Looks Weak
Margins matter. The more Endo Pharmaceuticals (NAS: ENDP) keeps of each buck it earns in revenue, the more money it has to invest in growth, fund new strategic plans, or (gasp!) distribute to shareholders. Healthy margins often separate pretenders from the best stocks in the market. That's why we check up on margins at least once a quarter in this series. I'm looking for the absolute numbers, comparisons to sector peers and competitors, and any trend that may tell me how strong Endo Pharmaceuticals' competitive position could be.
Here's the current margin snapshot for Endo Pharmaceuticals and some of its sector and industry peers and direct competitors.
Cephalon (NAS: CEPH)
Johnson & Johnson (NYS: JNJ)
Watson Pharmaceuticals (NYS: WPI)
Source: Capital IQ, a division of Standard & Poor's. TTM = trailing 12 months.
Unfortunately, that table doesn't tell us much about where Endo Pharmaceuticals has been, or where it's going. A company with rising gross and operating margins often fuels its growth by increasing demand for its products. If it sells more units while keeping costs in check, its profitability increases. Conversely, a company with gross margins that inch downward over time is often losing out to competition, and possibly engaging in a race to the bottom on prices. If it can't make up for this problem by cutting costs -- and most companies can't -- then both the business and its shares face a decidedly bleak outlook.
Of course, over the short term, the kind of economic shocks we recently experienced can drastically affect a company's profitability. That's why I like to look at five fiscal years' worth of margins, along with the results for the trailing 12 months, the last fiscal year, and last fiscal quarter. You can't always reach a hard conclusion about your company's health, but you can better understand what to expect, and what to watch.
Here's the margin picture for Endo Pharmaceuticals over the past few years.
Source: Capital IQ, a division of Standard & Poor's. Dollar amounts in millions. FY= fiscal year. TTM = trailing 12 months.
Because of seasonality in some businesses, the numbers for the last period on the right -- the TTM figures -- aren't always comparable to the FY results preceding them. To compare quarterly margins to their prior-year levels, consult this chart.
Source: Capital IQ, a division of Standard & Poor's. Dollar amounts in millions. FQ = fiscal quarter.
Here's how the stats break down:
- Over the past five years, gross margin peaked at 80% and averaged 76.3%. Operating margin peaked at 31.3% and averaged 29.2%. Net margin peaked at 21% and averaged 17.9%.
- TTM gross margin is 63.6%, 1,270 basis points worse than the five-year average. TTM operating margin is 27.3%, 190 basis points worse than the five-year average. TTM net margin is 12.1%, 580 basis points worse than the five-year average.
With recent TTM operating margins below historical averages, Endo Pharmaceuticals has some work to do.
If you take the time to read past the headlines and crack a filing now and then, you're probably ahead of 95% of the market's individual investors. To stay ahead, learn more about how I use analysis like this to help me uncover the best returns in the stock market. Got an opinion on the margins at Endo Pharmaceuticals? Let us know in the comments below.
- Add Endo Pharmaceuticals to My Watchlist.
- Add Cephalon to My Watchlist.
- Add Johnson & Johnson to My Watchlist.
- Add Watson Pharmaceuticals to My Watchlist.
At the time this article was published Seth Jaysonowned shares of the following at the time of publication: Johnson & Johnson. You can view his stock holdingshereHe is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool owns shares of Johnson & Johnson.Motley Fool newsletter serviceshave recommended buying shares of Johnson & Johnson.Motley Fool newsletter serviceshave recommended creating a diagonal call position in Johnson & Johnson. Try any of our Foolish newsletter servicesfree for 30 days. We Fools may not all hold the same opinions, but we all believe thatconsidering a diverse range of insightsmakes us better investors. The Motley Fool has adisclosure policy.
Copyright © 1995 - 2011 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.